Hot Features
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-con... Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.01 | 0.671140939597 | 1.49 | 1.55 | 1.43 | 26436 | 1.48830974 | CS |
| 4 | -0.3 | -16.6666666667 | 1.8 | 1.86 | 1.43 | 44141 | 1.59198598 | CS |
| 12 | -0.22 | -12.7906976744 | 1.72 | 2.33 | 1.43 | 96743 | 1.88899038 | CS |
| 26 | 0.11 | 7.91366906475 | 1.39 | 2.33 | 1.23 | 98026 | 1.64468629 | CS |
| 52 | -0.25 | -14.2857142857 | 1.75 | 2.33 | 1.23 | 119614 | 1.61500734 | CS |
| 156 | 0.41 | 37.6146788991 | 1.09 | 4.26 | 0.91 | 107218 | 1.9804639 | CS |
| 260 | -1.59 | -51.4563106796 | 3.09 | 6.19 | 0.61 | 135392 | 2.27906203 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.